FDA Biosimilars Approvals

Thursday April 23, 2020

FDA Biosimilars Approvals

BiosimilarApprovedLaunched
AVASTIN (BEVACIZUMAB)
Mvasi (bevacizumab-awwb)Sept-17Jul-19
Zirabev (bevacizumab-bvzr)Jun-19Dec-19
ENBREL (ETANERCEPT)
Erelzi (etanercept-szzs)Aug-16
Eticovo (etanercept-ykro)Apr-19
EPOGEN/PROCRIT (EPOETIN ALFA)
Retacrit (epoetinalfa-epbx)May-18Nov-18
HERCEPTIN (TRASTUZUMAB)
Ogivri (trastuzumab-dkst)Dec-17Dec-19
Herzuma (trastuzumab-pkrb)Dec-18Mar-20
Ontruzant (trastuzumab-dttb)Jan-19April-20
Trazimera (trastuzumab-qyyp)Mar-19Feb-20
Kanjinti (trastuzumab-anns)Jun-19Jul-19
HUMIRA (ADALIMUMAB)
Amjevita (adalimumab-atto)Sept-16
Cyltezo (adalimumab-adbm)Sept-16
Hyrimoz (adalimumab-adaz)Oct-18
Hadlima (adalimumab-bwwd)Jul-19
Abrilada (adalimumab-afzb)Nov-19
Hulio (adalimumab-fkjp)Jul-20
NEULASTA (PEGFILGRASTIM)
Fulphila (pegfilgrastim-jmdb)Jun-18Jun-18
Nyvepria (pegfilgrastim-apgf)Jun-20
Udenyca (pegfilgrastim-cbqv)Nov-18Jan-19
Ziextenzo (pegfilgrastim-bmez)Nov-19Dec-19
NEUPOGEN (FILGRASTIM)
Zarxio (filgrastim-sndz)Mar-15Sep-15
Nivestym (filgrastim-aafi)Jul-18Oct-18
REMICADE (INFLIXIMAB)
Inflectra (infliximab-dyyb)Apr-16Nov-16
Renflexis (infliximab-abda)Apr-17Jul-17
Ixifi (infliximab-qbtx)Dec-17
Avsola (infliximab-axxq)Dec-19
RITUXAN (RITUXIMAB)
Truxima (rituximab-abbs)Nov-18Nov-19
Ruxience (rituximab-pvvr)Jul-19Feb-20
Total: 28 approved, 17 launched*As of April 2020
Source: FDA

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.

  • This field is for validation purposes and should be left unchanged.

Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:

 

GRx+Biosims 2020

Planning + Ready: Join us November 9-11, 2020 for the premier scientific and regulatory event for the U.S. generics and biosimilars industries.

LEARN MORE

Recent Tweets

If the entire Affordable Care Act (#ACA) is overturned as unconstitutional, it could eliminate the Biologics Price Competition and Innovation Act (#BPCIA) and threaten the accessibility of life-saving treatments in the U.S.

Read more: https://www.washingtonpost.com/opinions/letters-to-the-editor/striking-down-obamacare-would-also-nix-generic-biologic-drugs/2020/06/28/44a4a630-b7c4-11ea-9a1d-d3db1cbe07ce_story.html

Load More...

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.

SIGN UP FOR OUR NEWSLETTER